318 related articles for article (PubMed ID: 27888626)
1. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.
Chien Y; Chien CS; Chiang HC; Huang WL; Chou SJ; Chang WC; Chang YL; Leu HB; Chen KH; Wang KL; Lai YH; Liu YY; Lu KH; Li HY; Sung YJ; Jong YJ; Chen YJ; Chen CH; Yu WC
Oncotarget; 2016 Dec; 7(52):87161-87179. PubMed ID: 27888626
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients.
Chien Y; Chou SJ; Chang YL; Leu HB; Yang YP; Tsai PH; Lai YH; Chen KH; Chang WC; Sung SH; Yu WC
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772700
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy.
Chen KH; Chien Y; Wang KL; Leu HB; Hsiao CY; Lai YH; Wang CY; Chang YL; Lin SJ; Niu DM; Chiou SH; Yu WC
Can J Cardiol; 2016 Oct; 32(10):1221.e1-1221.e9. PubMed ID: 26919792
[TBL] [Abstract][Full Text] [Related]
4. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.
Chou SJ; Yu WC; Chang YL; Chen WY; Chang WC; Chien Y; Yen JC; Liu YY; Chen SJ; Wang CY; Chen YH; Niu DM; Lin SJ; Chen JW; Chiou SH; Leu HB
Int J Cardiol; 2017 Apr; 232():255-263. PubMed ID: 28082092
[TBL] [Abstract][Full Text] [Related]
5. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.
Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM
J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613
[TBL] [Abstract][Full Text] [Related]
6. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
[TBL] [Abstract][Full Text] [Related]
7. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A).
Hsu TR; Sung SH; Chang FP; Yang CF; Liu HC; Lin HY; Huang CK; Gao HJ; Huang YH; Liao HC; Lee PC; Yang AH; Chiang CC; Lin CY; Yu WC; Niu DM
Orphanet J Rare Dis; 2014 Jul; 9():96. PubMed ID: 24980630
[TBL] [Abstract][Full Text] [Related]
8. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
9. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
10. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.
Itier JM; Ret G; Viale S; Sweet L; Bangari D; Caron A; Le-Gall F; Bénichou B; Leonard J; Deleuze JF; Orsini C
J Inherit Metab Dis; 2014 Nov; 37(6):1013-22. PubMed ID: 24850378
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
[TBL] [Abstract][Full Text] [Related]
12. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).
Lin HY; Huang CH; Yu HC; Chong KW; Hsu JH; Lee PC; Cheng KH; Chiang CC; Ho HJ; Lin SP; Chen SJ; Lin PK; Niu DM
J Inherit Metab Dis; 2010 Oct; 33(5):619-24. PubMed ID: 20821055
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
[TBL] [Abstract][Full Text] [Related]
15. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
[TBL] [Abstract][Full Text] [Related]
16. Late-onset and classic phenotypes of Fabry disease in males with the
Valtola K; Hedman M; Kantola I; Walls S; Helisalmi S; Maria M; Raivo J; Auray-Blais C; Kuusisto J
Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927868
[TBL] [Abstract][Full Text] [Related]
17. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
[TBL] [Abstract][Full Text] [Related]
18. Genetic epidemiological study doesn't support GLA IVS4+919G>A variant is a significant mutation in Fabry disease.
Chiang HL; Wang NH; Song IW; Chang CP; Wen MS; Chien YH; Hwu WL; Tsai FJ; Chen YT; Wu JY
Mol Genet Metab; 2017 May; 121(1):22-27. PubMed ID: 28377241
[TBL] [Abstract][Full Text] [Related]
19. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
[TBL] [Abstract][Full Text] [Related]
20. Correlations between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients with the Chinese Hotspot IVS4+919G>A Mutation: Data from the Fabry Outcome Survey.
Hsu TR; Chang FP; Chu TH; Sung SH; Bizjajeva S; Yu WC; Niu DM
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
